Dados B3Stocks › DASA3 PT

Saúde

DASA3 — DIAGNOSTICOS DA AMERICA SA

CNPJ 61.486.650/0001-83 · listed classes: DASA3 · CVM code 19623

-3.7P/E
0.6P/B
4.6EV/EBITDA
-7.7%FCF yield
-15.6%ROE 2025
4.2%ROIC 2025
P/E, P/B and EV/EBITDA priced at the session of 2026-03-26 (R$ 3.41), the first one after the 2025 filing became public on 2026-03-26 — point-in-time, not the 31 December price. pl_negativo

The full history, year by year

The arrow opens the path from the figure down to the line in the regulator's file. A cell with ! carries a caveat; a dash is a withheld figure — hover for the reason. Nothing is hidden.

indicator2010201120122013201420152016201720182019202020212022202320242025
ROE 15.9%!9.2%3.3%4.9%3.0%0.9%3.4%4.2%5.5%3.8%-4.4%-4.1%-5.3%-16.2%-15.7%-15.6%
ROIC 19.2%!11.6%4.6%5.3%4.2%2.5%!4.6%!6.2%7.1%7.5%1.7%!0.6%!5.0%!3.8%!4.4%!4.2%!
ROA 5.0%!4.7%2.0%2.9%1.8%0.5%1.9%2.4%2.8%1.6%-1.3%-1.2%-1.5%-4.3%-4.5%-5.0%
Gross margin 37.0%35.8%30.9%31.1%31.2%27.5%31.7%34.1%35.5%35.4%24.9%29.9%28.9%27.3%27.4%30.4%
EBIT margin 19.5%17.2%10.8%11.6%9.2%5.7%9.9%9.9%8.8%9.1%2.4%0.8%7.7%6.4%7.1%8.1%
Net margin 6.5%6.7%3.7%5.3%3.1%0.9%3.1%4.0%4.7%3.0%-2.1%-2.1%-3.0%-7.9%-7.8%-10.2%
Revenue growth (1y) 45.1%3.9%9.9%10.2%3.6%8.8%11.8%15.7%11.0%61.3%48.0%26.0%8.6%7.5%-27.1%
Revenue growth (5y CAGR) 13.2%6.9%8.5%10.0%10.1%20.3%27.9%31.0%29.4%28.6%9.7%
Net debt/EBITDA 1.18x1.63x2.13x1.99x1.88x2.24x1.30x2.13x2.41x2.28x4.10x3.96x3.94x4.06x3.45x2.45x
Current ratio 1.23x1.70x2.48x1.97x1.76x1.81x1.61x1.06x1.63x1.46x1.40x0.99x1.25x1.25x1.55x1.24x

The current year, quarter by quarter

As the company filed it in its interim report. The fourth quarter does not exist on its own in that filing — the closed year comes in the annual one, and we do not derive a Q4, so that a figure we computed never sits beside the figures the company reported. Filed on is the date the report became public, and the price is taken from it.

quarterrevenueprofitnet marginP/E TTMP/Bfiled on
2024T1!3,728.0-174.1-4.7%-2.20.362024-05-15
2024T2!3,955.7-100.9-2.6%-2.10.292024-08-14
2024T3!3,969.2-86.9-2.2%-1.90.202024-11-13
2025T1!3,826.3-111.5-2.9%-1.70.242025-06-12
2025T2!2,465.9-175.6-7.1%-1.50.242025-08-14
2025T3!2,608.599.93.8%-2.30.312025-11-13
2026T1!2,222.80.30.0%-3.80.572026-05-12
2026T2!2,223.5-31.2-1.4%-3.50.462026-08-13

Full series, every quarter: GET /empresas/DASA3/trimestres

Dividends per year

yearper sharepayments
2021R$ 0.58662
2019R$ 0.56341
2018R$ 0.56121
2017R$ 0.13992
2016R$ 0.10042
2015R$ 0.06291
2014R$ 0.10101
2013R$ 0.06601

Piotroski F-Score 4/9 (2025) — what each criterion means.

Restated filings for this company

The regulator overwrites the old version; we keep both. Figures in R$ millions: first filing on the left, restatement on the right.

fiscal yearaccountfirst filingrestated
2022DFC_MI 6.01751.6-317.1
2011DFC_MI 6.01-111.3153.3
2013DRE 3.012,487.52,447.8
2016BPA 15,021.85,061.1
2016BPP 25,021.85,061.1
2013DRE 3.02-1,714.6-1,683.1
2011BPA 14,064.14,032.7
2011BPP 24,064.14,032.7

This company appears in

Other companies in Healthcare

15 more with a page, same CVM sector — a classification of the regulator's, not ours.

Take this into your code

Everything on this page is also JSON: GET /empresas/DASA3/indicadores. WEGE3 is open for testing without a key; for the rest, create a free key (200 calls/day, no card).

Price coverage: 3,462 sessions, 2010-01-04 → 2026-09-04 · methodology · how we verify

Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 10:36 UTC. If this does not match /saude, you are reading a cached copy.